Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,515 signal articles · 196 in last 24h · 116,799 total before filter · latest 1h ago
196last 24h
1695last 7d
280● bullish (7d)
150● bearish (7d)
205publishers
AllMacro318Earnings761M&A100Regulatory25Product16Analyst24
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
MACOM Technology Solutions Q3 Earnings Call Highlights
MarketBeat11d agoneutral
MACOM Technology Solutions Q3 Earnings Call Highlights

MACOM Technology Solutions (NASDAQ:MTSI) reported record fiscal third-quarter results, citing strong demand across its data center, industrial and defense, and telecom markets. The company also issued fourth-quarter guidance that calls for another sequential increase in revenue, margins and adjusted

Lexicon Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat11d agoneutral
Lexicon Pharmaceuticals Q2 Earnings Call Highlights

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabet

MKS Q2 Earnings Call Highlights
MarketBeat11d agoneutral
MKS Q2 Earnings Call Highlights

MKS (NASDAQ:MKSI) reported second-quarter 2026 revenue of $1.25 billion, up 16% sequentially and 28% from a year earlier, as demand increased across semiconductor, electronics and packaging, and specialty industrial markets. Management said revenue and key profitability measures reached the high end

Lightbridge Q2 Earnings Call Highlights
MarketBeat11d agoneutral
Lightbridge Q2 Earnings Call Highlights

Lightbridge (NASDAQ:LTBR) reported progress in its nuclear fuel development program during the second quarter and first half of 2026, including the removal of its first irradiated fuel material samples from Idaho National Laboratory’s Advanced Test Reactor and steps toward commercial-scale fabricati

Ligand Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat11d agoneutral
Ligand Pharmaceuticals Q2 Earnings Call Highlights

Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering. Total revenue rose 34% year over year

Investing.com11d agoneutral
Atlassian rockets 23% after crushing earnings and flexing cloud & AI muscle

The company posted adjusted earnings per share of $1.87, beating the analyst consensus of $1.50 by $0.37. Revenue reached $1.77 billion, surpassing the $1.66 billion estimate and representing a 28% increase YoY from $1.38 billion in the same quarter last year. Cloud revenue grew 31% YoY to $1.21 billion, while Data Center revenue came in at $461.9 million, above the $414.6 million estimate.

Airbnb raises 2026 outlook after Q2 earnings top estimates
Proactive11d agoneutral
Airbnb raises 2026 outlook after Q2 earnings top estimates

Airbnb Inc (NASDAQ:ABNB, XETRA:6Z1) shares rose about 10% after Thursday’s closing bell after the alternative accommodation provider reported better-than-expected second quarter results and raised its full-year revenue and adjusted EBITDA margin guidance, citing continued strong travel...

JPMorgan resets SpaceX price target after earnings
TheStreet11d agoneutral
JPMorgan resets SpaceX price target after earnings

Wall Street had a simple question heading into SpaceX's first earnings report as a public company. Was the spending worth it? The answer came in the form of a single number that landed on Aug. 4 and immediately changed the tone of every conversation about the stock. The stock had been trading near ...

Iovance Biotherapeutics Q2 Earnings Call Highlights
MarketBeat11d agoneutral
Iovance Biotherapeutics Q2 Earnings Call Highlights

Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic

Immunovant Q1 Earnings Call Highlights
MarketBeat11d agoneutral
Immunovant Q1 Earnings Call Highlights

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant (NASDAQ:IMVT). Chief Executive Officer Matt

Himax Technologies Q2 Earnings Call Highlights
MarketBeat11d agoneutral
Himax Technologies Q2 Earnings Call Highlights

Himax Technologies (NASDAQ:HIMX) reported second-quarter 2026 results that exceeded its prior guidance, as stronger-than-expected automotive integrated-circuit sales lifted revenue, gross margin and profit. Revenue for the quarter totaled $227.4 million, up 14.2% sequentially and 5.9% from a year e